ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

Affiliations

• ¹ Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK.
• ² Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Cancer Centre, Boston, USA.
• ³ Department of Pathology, Medical University Vienna, Austria.
• ⁴ Department of Urology, Charité Universitätsmedizin, Berlin, Germany; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
• ⁵ Royal Marsden Hospital, Institute of Cancer Research, London, UK.
• ⁶ Department of Medical Oncology, Université Paris-Saclay and Gustave Roussy, Villejuif, France.
• ⁷ Vita-Salute San Raffaele University, Milan; Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
• ⁸ Department of Medical Oncology, University Hospital Virgen del Rocio, Seville, Spain.
• ⁹ Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.
• ¹⁰ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York; Department of Urology, University of Texas Southwestern, Dallas, USA; Division of Urology, Department of Special Surgery, University of Jordan, Amman, Jordan.
• ¹¹ Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK.
• ¹² Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
• ¹³ Oncology Institute of Southern Switzerland (EOC-IOSI), Bellinzona; Università della Svizzera italiana (USI), Lugano, Switzerland.